MOACM
MDGL icon

Mutual of America Capital Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Mutual of America Capital Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.32M Sell
12,069
-31
-0.3% -$14.8K 0.07% 325
2025
Q4 		$7.05M Sell
12,100
-79
-0.6% -$40.4K 0.07% 302
2025
Q3 		$5.59M Sell
12,179
-130
-1% -$48.5K 0.06% 399
2025
Q2 		$3.73M Buy
12,309
+1,046
+9% +$312K 0.04% 559
2025
Q1 		$3.73M Buy
11,263
+31
+0.3% +$10.2K 0.04% 553
2024
Q4 		$3.47M Sell
11,232
-10
-0.1% -$2.81K 0.04% 630
2024
Q3 		$2.39M Sell
11,242
-106
-0.9% -$27.1K 0.03% 823
2024
Q2 		$3.18M Sell
11,348
-491
-4% -$117K 0.03% 684
2024
Q1 		$3.16M Sell
11,839
-964
-8% -$227K 0.03% 706
2023
Q4 		$2.96M Sell
12,803
-572
-4% -$100K 0.03% 716
2023
Q3 		$1.95M Sell
13,375
-796
-6% -$150K 0.02% 878
2023
Q2 		$3.27M Sell
14,171
-1,082
-7% -$293K 0.04% 687
2023
Q1 		$3.7M Sell
15,253
-701
-4% -$191K 0.04% 627
2022
Q4 		$4.63M Buy
15,954
+215
+1% +$21K 0.06% 489
2022
Q3 		$1.02M Sell
15,739
-1,430
-8% -$99.4K 0.01% 1024
2022
Q2 		$1.23M Sell
17,169
-129
-0.7% -$9.48K 0.02% 1010
2022
Q1 		$1.7M Sell
17,298
-752
-4% -$63.4K 0.02% 987
2021
Q4 		$1.53M Sell
18,050
-169
-0.9% -$13.9K 0.02% 1019
2021
Q3 		$1.45M Sell
18,219
-264
-1% -$22.8K 0.01% 1026
2021
Q2 		$1.8M Sell
18,483
-794
-4% -$94K 0.02% 1008
2021
Q1 		$2.25M Sell
19,277
-1,066
-5% -$124K 0.02% 914
2020
Q4 		$2.26M Buy
20,343
+2,821
+16% +$345K 0.03% 854
2020
Q3 		$2.08M Sell
17,522
-3,009
-15% -$327K 0.03% 802
2020
Q2 		$2.33M Sell
20,531
-610
-3% -$60K 0.03% 758
2020
Q1 		$1.41M Sell
21,141
-930
-4% -$77.5K 0.02% 861
2019
Q4 		$2.01M Sell
22,071
-153
-0.7% -$14.8K 0.03% 902
2019
Q3 		$1.92M Buy
22,224
+7,569
+52% +$710K 0.03% 878
2019
Q2 		$1.54M Buy
14,655
+10
+0.1% +$1.07K 0.02% 982
2019
Q1 		$1.83M Buy
14,645
+10,445
+249% +$1.3M 0.03% 910
2018
Q4 		$473K Hold
4,200
– – 0.01% 1124
2018
Q3 		$899K Hold
4,200
– – 0.01% 1101
2018
Q2 		$1.18M Buy
+4,200
New +$738K 0.02% 1076
2013
Q4 		– Sell
-4,192
Closed -$926K – 1234
2013
Q3 		$926K Buy
4,192
+629
+18% +$134K 0.03% 946
2013
Q2 		$622K Buy
+3,563
New +$929K 0.02% 1023

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Mutual of America Capital Management's MDGL Position: Q1 2026 in Review

Mutual of America Capital Management reduced its Madrigal Pharmaceuticals (MDGL) stake by 0.26% in Q1 2026, selling an estimated $14.8K and leaving 12,069 shares worth $6.32M. The position accounts for 0.07% of the portfolio, ranked #325.

Mutual of America Capital Management first reported a position in MDGL in Q2 2013 and has held it in 34 quarters since. The position peaked at $7.05M in Q4 2025. 378 funds tracked by Wall St. Rank hold MDGL as of Q1 2026.

  • Mutual of America Capital Management held 12,069 shares of Madrigal Pharmaceuticals worth $6.32M as of Q1 2026.
  • Mutual of America Capital Management sold 31 Madrigal Pharmaceuticals shares in Q1 2026, an estimated $14.8K.
  • Madrigal Pharmaceuticals made up 0.07% of Mutual of America Capital Management's portfolio in Q1 2026, its #325 holding.
  • Mutual of America Capital Management first reported a position in Madrigal Pharmaceuticals in Q2 2013 and has held it in 34 quarters since.
  • Mutual of America Capital Management's Madrigal Pharmaceuticals position peaked at $7.05M in Q4 2025.
  • 378 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2026.

Based on Mutual of America Capital Management's 13F filing for Q1 2026, filed 7 May 2026.